We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 12 oktober 2018

The Lancet: [Articles] Prognostic value of end-of-induction PET response after first-line immunochemotherapy for foll...

[Articles] Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
Our results suggest that PET is a better imaging modality than contrast-enhanced CT for response assessment after first-line immunochemotherapy in patients with follicular lymphoma. PET assessment according to Lugano 2014 response criteria provides a platform for investigation of response-adapted therapeutic approaches. Additional supportive data are welcomed.
Read more

[Comment] Personalised approach in follicular lymphoma
Follicular lymphoma is the most common subtype of indolent B-cell lymphoma, and patient outcomes are highly heterogeneous, with 20–30% of patients having aggressive (rather than indolent) disease.1 These high-risk patients would benefit from a personalised approach to their care if validated and accurate prognostic tools were available to identify them as soon as possible after diagnosis. Although many prognostic tools and indices to predict survival in follicular lymphoma have been developed in the past 20 years, none of them have yet proven useful in therapeutic decision making.
Read more

[Articles] Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial
In this cohort of patients with intermediate-risk and high-risk localised prostate cancer, NHT plus WPRT improved progression-free survival compared with NHT plus PORT and WPRT plus AHT at long-term follow-up albeit increased risk of grade 3 or worse intestinal toxicity. Interactions between radiotherapy and hormonal therapy suggests that WPRT should be avoided without NHT.
Read more

[Comment] Pelvic radiotherapy in prostate cancer: an unresolved question
The question of whether to irradiate the pelvis or not in primary prostate cancer is essential to daily practice and subject to many discussions in every radiation oncology department. Until now, most clinicians who treated the pelvis with radiotherapy did so mostly on the basis that important, multicentre, randomised trials in favour of combining androgen deprivation therapy (ADT) and external beam radiotherapy (EBRT) over a control group often included pelvic radiotherapy in the EBRT field.1 With time, treatment for the pelvis became more sophisticated with the realisation that nodes at risk were often excluded from preventive treatment fields.
Read more

[News] Combination therapy for first relapse of multiple myeloma
An oral regimen of pomalidomide–cyclophosphamide–dexamethasone (PCD) seems to be active and safe for first relapse in patients with multiple myeloma, according to a recent study.
Read more